Samuel H. Adams

DICOM Grid, Inc. operates as a healthcare Information Technology company. It engages in the development of comprehensive medical image management and exchange software solutions. The firm offers cloud platform for medical imaging information and applications. Its products and services include hospitals and health systems, medical groups and practices, radiology practices, contract research organizations and ambra service difference. The firm’s solutions include health systems, community hospitals, healthcare service providers, medical specialties and interoperability. The company was founded by C. Roger Bird and Shahram Partovi in 2006 and is headquartered in New York, NY.

TrueVision Systems, Inc. provides 3D vision systems for microscopes. It offers pre-operative image registration, intra-operative eye tracking, incision location calculator, surgeon incision preferences and default settings, Phaco SIA compensator, and 3D overlay depth control. The company was founded by Michael A. Weissman on October 14, 2003 and is headquartered in Goleta, CA.

DiscGenics, Inc. operates as a regenerative medicine company. It focuses on the devlopment of therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. The company was founded in 2007 and is headquartered in Salt Lake City, UT.

Part of ITOCHU Corp., Flanagan Instruments, Inc. is a medical device manufacturer. The company is based in New Orleans, LA. The company was founded by J. Flagg Flanagan. Flanagan Instruments was acquired by ITOCHU Corp. on June 13, 2005.

Barrow Neurological Institute is a premier destination for neurology and neurosurgery. The non-profit company is based in Phoenix, AZ. The company's team of neurological specialists provides advanced care to their patients.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.